Fortress Biotech: Cash Above Market Cap And Royalty Upside Make This A Speculative Buy

Fortress Biotech is trading below its cash balance, offering deep value relative to its assets and recent financial improvements. FBIO's Q1 2026 saw a dramatic cash increase to $255.8M and net profit from the ZYCUBO PRV sale, though this was a one-off event. Journey Medical, with 36% FBIO ownership, anchors commercial revenue and shows strong growth, especially from Emrosi prescriptions. FBIO's portfolio offers royalty and milestone optionality, but risks include cash burn, portfolio complexity, and reliance on Journey Medical; I rate it a speculative Buy.

Fortress Biotech, Inc. (FBIO) may not be a low-risk biotech player, but currently it looks undervalued when compared to its current assets, cash position, and the royalties the company possesses. The structure and interlinkages within the company are complex, but This article was written by DCF Value Investor 61 Followers Follow I'm DCF Value Investor a passionate individual analyst with unique ideas that cover all types of stocks and commodities. I focus on companies fundamentals and valuation, to deliver a proper investment analysis. My ideas explore a different point of view for undervalued opportunities. Although I cover all types of stocks, the sectors I prefer are materials, technology and real estate. My research process begins with screening for companies that appear undervalued based on their balance sheet, income statement and cash flow statement. From there I conduct a fundamental analysis, including valuation ratios and industry trends. Through my analysis, I aim to help my readers to make better investment decisions. As an independent writer, I write with a particular perspective, bringing fresh ideas to the platform. My ideas keen all types of readers with her intense research in the stock I'm covering, the investment thesis on my articles is solid as it is back on fundamentals and the whole concept on my pieces are based on value investing. My motivation for writing on Seeking Alpha is to offer a different perspective from Wall Street, writing about hidden opportunities in the market. Investigating over hyped stocks in the market, digging into financials and valuation with my own analysis are my passion.